Utility of supplemental screening with breast ultrasound in asymptomatic women with dense breast tissue who are not at high risk for breast cancer

Geetika A Klevos, Fernando Collado-Mesa, Jose M Net, Monica M Yepes
Department of Radiology, Sylvester Comprehensive Cancer Center, University of Miami Hospital and Clinics, Miami, Florida, USA

Correspondence: Dr. Geetika A Klevos, Department of Radiology, Mammography Division, Sylvester Comprehensive Cancer Center, University of Miami Hospital and Clinics, Miami, Florida, USA. E-mail: gmohin@med.miami.edu

Abstract

Objective: To assess the results of an initial round of supplemental screening with hand-held bilateral breast ultrasound following a negative screening mammogram in asymptomatic women with dense breast tissue who are not at high risk for breast cancer.

Materials and Methods: A retrospective, Health Insurance Portability and Accountability Act compliant, Institutional Research Board approved study was performed at a single academic tertiary breast center. Informed consent was waived. A systematic review of the breast imaging center database was conducted to identify and retrieve data for all asymptomatic women, who were found to have heterogeneously dense or extremely dense breast tissue on screening bilateral mammograms performed from July 1, 2010 through June 30, 2012 and who received a mammographic final assessment American College of Radiology’s (ACR) Breast Imaging Reporting and Data System (BI-RADS) category 1 or BI-RADS category 2. Hand-held screening ultrasound was performed initially by a technologist followed by a radiologist. Chi-square and t-test were used and statistical significance was considered at P < 0.05.

Results: A total of 1210 women were identified. Of these, 394 underwent the offered supplemental screening ultrasound. BI-RADS category 1 or 2 was assigned to 323 women (81.9%). BI-RADS category 3 was assigned to 50 women (12.9%). A total of 26 biopsies/aspirations were recommended and performed in 26 women (6.6%). The most common finding for which biopsy was recommended was a solid mass (88.5%) with an average size of 0.9 cm (0.5–1.7 cm). Most frequent pathology result was fibroadenoma (60.8%). No carcinoma was found.

Conclusion: Our data support the reported occurrence of a relatively high number of false positives at supplemental screening with breast ultrasound following a negative screening mammogram in asymptomatic women with dense breast tissue, who are not at a high risk of developing breast cancer, and suggests that caution is necessary in establishing wide implementation of this type of supplemental screening for all women with dense breast tissue without considering other risk factors for breast cancer.

Key words: Breast ultrasound; dense breasts; screening

Access this article online

Quick Response Code:

Website: www.ijri.org

DOI: 10.4103/0971-3026.202962

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

For reprints contact: reprints@medknow.com

Cite this article as: Klevos GA, Collado-Mesa F, Net JM, Yepes MM. Utility of supplemental screening with breast ultrasound in asymptomatic women with dense breast tissue who are not at high risk for breast cancer. Indian J Radiat Imaging 2017;27:52-8.
Introduction

The sensitivity of screening mammography is decreased by the presence of dense breast tissue, as defined by the American College of Radiology’s (ACR) Breast Imaging Reporting and Data System (BI-RADS). In addition, some studies indicate that dense breast tissue increases breast cancer risk. Published studies on hand-held breast ultrasound as a supplemental test to screening mammography in women with dense breast tissue report an incremental cancer detection rate of approximately 2–4/1000 examined women. Breast cancers detected by supplemental ultrasound have been reported to be small invasive cancers, with a high proportion of node-negative cases. However, these studies have important differences in methodology, including varied inclusion criteria and varied qualification of ultrasound performers.

Recently, and mainly as a result of efforts by grassroots advocacy groups, several states in the United States (US) have enacted legislation requiring that, following screening mammography, all women with dense breasts be informed of their breast tissue density and that supplemental screening tests, such as breast ultrasound, should be discussed with them by their providers. In the US, this would entail supplemental screening of more than 40% of women over 40 years of age.

The purpose of our study was to retrospectively assess the results of an initial round of supplemental screening with hand-held bilateral breast ultrasound performed consecutively by a technologist and a radiologist following a negative bilateral mammogram in asymptomatic women with dense breast tissue who were not at a high risk of breast cancer, as defined by the American College of Radiology (ACR) and the Society of Breast Imaging (SBI).

Materials and Methods

A retrospective, Health Insurance Portability and Accountability Act (HIPAA)-compliant and Institutional Research Board (IRB)-approved study was performed. The need for informed consent was waived.

Study period and participants

A systematic review of the breast imaging center’s database was performed to identify all asymptomatic women who were reported to have heterogeneously dense [Figure 1A and B] or extremely dense [Figure 2A and B] breast tissue, as defined by the BI-RADS Atlas on screening bilateral mammogram performed from July 1, 2010 through June 30, 2012 and who received a final assessment BI-RADS category 1, negative or BI-RADS category 2, benign.

At the time of the study, the breast imaging center was initiating a policy by which a paragraph was added to the radiologist’s mammogram report to the referring physician of women meeting the above criteria, stating “Given the dense breast tissue, which may lower the sensitivity of mammography, supplemental screening with breast ultrasound is offered.”

At our facility, women at high risk for breast cancer (20–25% or greater lifetime risk of breast cancer), as defined by the American Cancer Society, are recommended to undergo supplemental screening with breast magnetic resonance imaging (MRI), and thus were not included in this study. Further, not included were women with a personal history of breast cancer, who at our institution undergo diagnostic, not screening mammography, for life.

Data collection

The following data was retrieved for all women included in the study: Age, race, family history of breast cancer, personal history of breast biopsy, personal history of biopsy-proven high risk lesion of the breast, age at menarche, age at menopause, parity, age of first pregnancy, and use of hormones (hormonal contraceptives and hormone replacement therapy).

In addition, for women who received the offered breast ultrasound, the following data was also retrieved based on the BI-RADS Atlas: final assessment BI-RADS category of the breast ultrasound exam; if biopsy was...
Klevos, et al.: Supplemental screening breast ultrasound in asymptomatic non-high risk women with dense breast tissue

Breast imaging studies and interpretation
Every screening bilateral mammogram was obtained as 2D digital study on a Selenia® Hologic® unit and was performed by one of six mammography technologists, all of whom are certified in mammography (registered by the American Registry of Radiologic Technologists), with an experience of 17, 11, 6, 6, 5, and 4 years, and was interpreted by one of the four board certified breast imagers, with 30, 11, 3, and 2 years of experience in breast imaging.

Every supplemental bilateral breast ultrasound examination was obtained less than six months from the screening mammogram and was obtained on a dedicated breast ultrasound unit (GE LOGIC E9) with a high-resolution linear-array transducer (6–15 MHz) by one of the six technologists, two of whom are RDMS certified (Registered Diagnostic Medical Sonographer) and one of whom is ARRT certified (American Registry of Radiologic Technologists). Two of them with experience in breast sonography for 10 years each, one with 6 years, two with 5 years of experience each, and one with 1-year experience.

The breast ultrasound was performed in a standardized hand-held manner with overlapping scans in the radial and antiradial planes, extending from the nipple to the posterior breast tissue. If no abnormal findings were identified, images were documented in the 12-, 3-, 6-, and 9-o’clock positions, as well as in the retroareolar region. If any finding was present, images of each finding were obtained and measured in three dimensions.

Immediately after the breast ultrasound exam by the technologist, the exam was repeated by one of the four board-certified dedicated breast imaging radiologists. The same breast imaging radiologist interpreted the mammogram and ultrasound for each patient. The breast imager performed a repeat complete ultrasound scan of the breasts in real time, regardless of whether or not the technologist identified any abnormality and was not blinded to the results of the screening mammogram and the patient’s history and was able to review the breast ultrasound images obtained by the technologist.

Ultrasound-guided procedures
All ultrasound-guided breast biopsies were performed either with a 14-gauge automated core biopsy needle (Achieve, Cardinal Health, Dublin, Ohio), or a 9 or 12-gauge vacuum-assisted core biopsy needle (Atec, Hologic, Bedford, MA). All cyst aspirations were performed with an 18 Gauge needle.

Statistical analysis
The Chi-square test was used for discrete data and the t-test for continuous data. Statistically significant
Results

During the study period, a total of 2469 asymptomatic women not at high risk of breast cancer and without a personal history of breast cancer and who received a final assessment BI-RADS category 1, negative, or BI-RADS category 2, benign, at screening bilateral mammogram were evaluated. Of these, 1210 (49%) were found to have heterogeneously dense or extremely dense breast tissue. Of these, 394 (32.5%) women underwent the offered supplemental screening bilateral breast ultrasound.

At the initial round of supplemental screening breast ultrasound, 323 women (81.9%) received a final assessment BI-RADS category 1, negative [Figure 3], or BI-RADS category 2, benign [Figure 4A and B] and were recommended to undergo routine yearly screening; whereas 50 women (12.9%) received a final assessment BI-RADS category 3, probably benign [Figure 5A-C] and were recommended to undergo short-term follow-up with breast ultrasound in 6 months [Table 1]. Two of the women who received a BI-RADS category 3 requested biopsy, which was performed. A BI-RADS category 4, suspicious [Figures 6A-C and 7A and B], with recommendation for biopsy was assigned to 19 women (4.8%) [Table 1]. A total of 21 women (5.3%) underwent an ultrasound-guided procedure as a result of the initial round of supplemental screening bilateral breast ultrasound. No BI-RADS category 5, highly suspicious, was assigned.

As a result of the first two consecutive short-term follow-ups with breast ultrasound recommended to patients who were assigned a BI-RADS category 3, five more biopsies were recommended and performed; four biopsy recommendations were generated at the first short-term follow-up cycle and one at the second short-term follow-up cycle [Table 1]. All of them were due to interval increase in size of the initial finding. Overall, a total of 26 women (6.6%) were recommended a biopsy, which was performed in all of them.

The most common ultrasound finding for which biopsy was recommended and performed was a solid mass (88.5%) with an average size of 0.9 cm (range: 0.5–1.7 cm) [Table 2]. The most frequent pathology result was fibroadenoma (60.8%). Fine needle aspiration of a complicated cyst in two

Figure 4 (A and B): (A) Bilateral screening breast ultrasound showing a simple cyst in a patient with breast implants-Category BIRADS 2. Benign (B) Bilateral screening breast ultrasound showing a simple cyst with color doppler in the same patient with breast implants-Category BIRADS 2. Benign

Figure 5 (A-C): (A) Bilateral screening breast ultrasound showing a benign appearing mass, likely a fibroadenoma for which a six month follow up ultrasound was recommended-Category BIRADS 3. Probably Benign (B) Bilateral screening breast ultrasound showing a benign appearing mass, likely a fibroadenoma for which a six month follow up ultrasound was recommended-Category BIRADS 3. Probably Benign (C) Bilateral screening breast ultrasound showing a benign appearing mass, likely a fibroadenoma with color doppler for which a six month follow up ultrasound was recommended-Category BIRADS 3. Probably Benign
Klevos, et al.: Supplemental screening breast ultrasound in asymptomatic non-high risk women with dense breast tissue

Our study includes only asymptomatic women with dense breast tissue who are not at high risk for breast cancer, which represent the majority of women with dense breast tissue who undergo screening mammography for breast cancer. Some prior studies on supplemental screening with breast ultrasound for dense breast tissue have only included women at a high risk for breast cancer, whereas others have included symptomatic women and unilateral breast ultrasound obtained in women with known mammographic abnormalities in the contralateral breast or even in a different quadrant of the ipsilateral breast.[6‑18] Moreover, it has been pointed out that there may be methodological flaws in the numerous studies which have previously suggested a link between breast density and the risk of breast cancer. This may be in part because of the problem of trying to extract 3D information from 2D images as stated by Kopans.[22]

Table 1: BI-RADS category at initial round of supplemental screening breast ultrasound and at recommended subsequent short-term follow-ups

<table>
<thead>
<tr>
<th>Ultrasound BI-RADS Assessment Category</th>
<th>At initial screening bilateral breast ultrasound (n=394)</th>
<th>At 1st short-term follow-up at 6 months for BI-RADS 3 (n=50)</th>
<th>At 2nd short-term follow-up at 12 months for BI-RADS 3 (n=36)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>37 (9.5%)</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>2</td>
<td>286 (72.6%)</td>
<td>10 (17.6%)</td>
<td>11 (55.5%)</td>
</tr>
<tr>
<td>3</td>
<td>50 (12.9%)</td>
<td>36 (70.5%)</td>
<td>23 (30.5%)</td>
</tr>
<tr>
<td>4</td>
<td>19 (4.8%)</td>
<td>4 (9.8%)</td>
<td>1 (2.7%)</td>
</tr>
<tr>
<td>5</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Lost to follow-up</td>
<td>n/a</td>
<td>1 of 50 (1.9%)</td>
<td>1 of 36 (2.7%)</td>
</tr>
</tbody>
</table>

n/a: Not applicable

patients (11.5%) was performed and resulted in complete resolution of the cyst with nonsuspicious fluid [Table 2]. No carcinoma was found at biopsy. Moreover, no interval carcinoma was found at 12-month follow-up mammogram.

Discussion

Prior studies on this topic have differences in the qualification of the ultrasound exam performers, with some performed only by the radiologist, some only by the technologist, and some by both.[6‑18] Performing the supplemental hand-held screening breast ultrasound consecutively by two performers, first by a technologist and then by the...
interpreting radiologist, as in our study, likely serves to elucidate most mammographically occult findings; however, it is time consuming and represents a burden on the already limited healthcare resources in a busy clinical practice.

An important methodological similarity between our study and some of the prior studies is using the biopsy results and the results of a 1-year follow-up as a reference standard to assess for false negative results, including the occurrence of interval cancers.[10-13]

Participants in our study were slightly younger (mean age of 47.3 years) as compared to those in other studies with a mean age of participants ranging from 51.2 to 55.2 years.[10,12,16-18]

Our results have several similarities to the results of previous studies, including the proportion of subjects with BI-RADS categories 1, 2, and 3, the biopsy rate, and that fibroadenoma and stromal fibrosis accounted for most pathology findings.[6,9] Moreover, in concurrence with prior studies the small number of the ultrasound findings that required further evaluation with biopsy, which ultimately is in concordance with the expected small number of the mammographically occult abnormalities that were found with supplemental breast ultrasound.[6-18]

Limitations of our study include a small population size, which is likely responsible for the fact that no carcinoma was found. There is only one published study in which the population size is smaller than ours and in which additional breast carcinoma was found with supplemental ultrasound. However, unlike our study, that study included participants with a personal history of breast cancer.[13]

<table>
<thead>
<tr>
<th>Ultrasound BI-RADS Category</th>
<th>Ultrasound finding</th>
<th>Size (cm)</th>
<th>Shape</th>
<th>Margins</th>
<th>Internal echogenicity</th>
<th>Orientation</th>
<th>Posterior features</th>
<th>Biopsy results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Recommended/performed at initial screening breast ultrasound</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3*</td>
<td>Mass</td>
<td>0.7</td>
<td>Oval</td>
<td>Circumscribed</td>
<td>Hypoechoic</td>
<td>Parallel</td>
<td>None</td>
<td>Fibroadenoma</td>
</tr>
<tr>
<td>3*</td>
<td>Mass</td>
<td>1.4</td>
<td>Oval</td>
<td>Circumscribed</td>
<td>Hypoechoic</td>
<td>Parallel</td>
<td>None</td>
<td>Fibroadenoma</td>
</tr>
<tr>
<td>4A</td>
<td>Mass</td>
<td>0.9</td>
<td>Oval</td>
<td>Circumscribed</td>
<td>Hypoechoic</td>
<td>Parallel</td>
<td>None</td>
<td>Fibroadenoma</td>
</tr>
<tr>
<td>4A</td>
<td>Mass</td>
<td>0.9</td>
<td>Oval</td>
<td>Circumscribed</td>
<td>Hypoechoic</td>
<td>Parallel</td>
<td>None</td>
<td>Fibroadenoma</td>
</tr>
<tr>
<td>4A</td>
<td>Septated cyst</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Fibrocystic changes</td>
</tr>
<tr>
<td>4A</td>
<td>Mass</td>
<td>0.9</td>
<td>Oval</td>
<td>Lobulated</td>
<td>Hypoechoic</td>
<td>Parallel</td>
<td>None</td>
<td>Fibroadenoma</td>
</tr>
<tr>
<td>4A</td>
<td>Mass</td>
<td>1.0</td>
<td>Oval</td>
<td>Circumscribed</td>
<td>Hypoechoic</td>
<td>Parallel</td>
<td>Shadowing</td>
<td>Fibroadenoma</td>
</tr>
<tr>
<td>4A</td>
<td>Mass</td>
<td>0.7</td>
<td>Oval</td>
<td>Circumscribed</td>
<td>Hypoechoic</td>
<td>Parallel</td>
<td>None</td>
<td>Fibroadenoma</td>
</tr>
<tr>
<td>4A</td>
<td>Complicated cyst</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Fluid not suspicious</td>
</tr>
<tr>
<td>4A</td>
<td>Complicated cyst</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Fluid not suspicious</td>
</tr>
<tr>
<td>4A</td>
<td>Mass</td>
<td>1.2</td>
<td>Oval</td>
<td>Lobulated</td>
<td>Hypoechoic</td>
<td>Parallel</td>
<td>None</td>
<td>Fibroadenoma</td>
</tr>
<tr>
<td>4A</td>
<td>Mass</td>
<td>1.0</td>
<td>Oval</td>
<td>Circumscribed</td>
<td>Hypoechoic</td>
<td>Parallel</td>
<td>None</td>
<td>Fibroadenoma</td>
</tr>
<tr>
<td>4A</td>
<td>Mass</td>
<td>1.0</td>
<td>Oval</td>
<td>Lobulated Microcysts</td>
<td>Mixed</td>
<td>Parallel</td>
<td>None</td>
<td>Apocrine microcysts</td>
</tr>
<tr>
<td>4A</td>
<td>Mass</td>
<td>1.0</td>
<td>Oval</td>
<td>Circumscribed</td>
<td>Hypoechoic</td>
<td>Parallel</td>
<td>None</td>
<td>Fibroadenoma</td>
</tr>
<tr>
<td>4B</td>
<td>Mass</td>
<td>0.6</td>
<td>Irregular</td>
<td>Angular</td>
<td>Hypoechoic</td>
<td>Parallel</td>
<td>None</td>
<td>No evidence of carcinoma in intramammary lymph node</td>
</tr>
<tr>
<td>4B</td>
<td>Mass</td>
<td>1.1</td>
<td>Irregular</td>
<td>Angular</td>
<td>Hypoechoic</td>
<td>Parallel</td>
<td>None</td>
<td>Fibroadenoma</td>
</tr>
<tr>
<td>4B</td>
<td>Mass</td>
<td>1.0</td>
<td>Irregular</td>
<td>Angular</td>
<td>Hypoechoic</td>
<td>Parallel</td>
<td>None</td>
<td>Fibrocystic changes</td>
</tr>
<tr>
<td>4C</td>
<td>Mass</td>
<td>1.0</td>
<td>Irregular</td>
<td>Indistinct</td>
<td>Hypoechoic</td>
<td>Parallel</td>
<td>None</td>
<td>Fibroadenoma</td>
</tr>
<tr>
<td>4C</td>
<td>Mass</td>
<td>1.7</td>
<td>Irregular</td>
<td>Angular</td>
<td>Hypoechoic</td>
<td>Parallel</td>
<td>Shadowing</td>
<td>Stromal fibrosis</td>
</tr>
<tr>
<td>4C</td>
<td>Architectural distortion</td>
<td>0.7</td>
<td>Irregular</td>
<td>Irregular</td>
<td>Hypoechoic</td>
<td>Not parallel</td>
<td>Shadowing</td>
<td>Stromal fibrosis</td>
</tr>
<tr>
<td>4C</td>
<td>Mass</td>
<td>0.5</td>
<td>Irregular</td>
<td>Irregular</td>
<td>Hypoechoic</td>
<td>Not parallel</td>
<td>Shadowing</td>
<td>Stromal fibrosis</td>
</tr>
</tbody>
</table>

Recommended/Performed at 6-month follow-up

<table>
<thead>
<tr>
<th>Ultrasound BI-RADS Category</th>
<th>Ultrasound finding</th>
<th>Size (cm)</th>
<th>Shape</th>
<th>Margins</th>
<th>Internal echogenicity</th>
<th>Orientation</th>
<th>Posterior features</th>
<th>Biopsy results</th>
</tr>
</thead>
<tbody>
<tr>
<td>4A</td>
<td>Mass</td>
<td>1.2</td>
<td>Oval</td>
<td>Circumscribed</td>
<td>Hypoechoic</td>
<td>Parallel</td>
<td>None</td>
<td>Fibroadenoma</td>
</tr>
<tr>
<td>4A</td>
<td>Mass</td>
<td>1.0</td>
<td>Oval</td>
<td>Circumscribed</td>
<td>Hypoechoic</td>
<td>Parallel</td>
<td>None</td>
<td>Stromal fibrosis</td>
</tr>
<tr>
<td>4A</td>
<td>Mass</td>
<td>1.6</td>
<td>Oval</td>
<td>Circumscribed</td>
<td>Hypoechoic</td>
<td>Parallel</td>
<td>None</td>
<td>Fibroadenoma</td>
</tr>
<tr>
<td>4B</td>
<td>Mass</td>
<td>0.8</td>
<td>Round</td>
<td>Microlobulated</td>
<td>Hypoechoic</td>
<td>Not parallel</td>
<td>Shadowing</td>
<td>Stromal fibrosis</td>
</tr>
</tbody>
</table>

Recommended/Performed at 12-month follow-up

<table>
<thead>
<tr>
<th>Ultrasound BI-RADS Category</th>
<th>Ultrasound finding</th>
<th>Size (cm)</th>
<th>Shape</th>
<th>Margins</th>
<th>Internal echogenicity</th>
<th>Orientation</th>
<th>Posterior features</th>
<th>Biopsy results</th>
</tr>
</thead>
<tbody>
<tr>
<td>4B</td>
<td>Mass</td>
<td>0.9</td>
<td>Oval</td>
<td>Microlobulated</td>
<td>Hypoechoic</td>
<td>Parallel</td>
<td>None</td>
<td>Adenosis</td>
</tr>
</tbody>
</table>

*Two patients with BI-RADS 3 at initial breast ultrasound requested biopsy
Conclusion

In conclusion, our results confirm some of the reported disadvantages of performing supplemental screening with breast ultrasound, in particular the high false-positive rate and a relatively high rate of short interval follow-up, and support the expressed opinions that caution should be exercised when recommending supplemental screening with hand-held bilateral breast ultrasound for all asymptomatic women with dense breast tissue without taking into account other risk factors, the expected large number of women who would undergo this additional test, and the added costs to the healthcare system.[23-27]

Acknowledgement

The authors would like to acknowledge medical students Mohammed Ezuddin, Jessica Schmidtman and Rachel Franklyn for their help with data collection.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

References